96 related articles for article (PubMed ID: 30758651)
21. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
22. A phase I study investigation of metabolism, and disposition of [
Liu Y; Liu L; Liu L; Wang T; Guo L; Wang Y; Gao Z; Shu Y
Cancer Chemother Pharmacol; 2020 May; 85(5):907-915. PubMed ID: 32266457
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
[TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
25. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
28. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
29. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
30. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
Kim KA; Park SJ; Kim C; Park JY
Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
Naing A; Aghajanian C; Raymond E; Olmos D; Schwartz G; Oelmann E; Grinsted L; Burke W; Taylor R; Kaye S; Kurzrock R; Banerji U
Br J Cancer; 2012 Sep; 107(7):1093-9. PubMed ID: 22935583
[TBL] [Abstract][Full Text] [Related]
32. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
34. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
35. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
37. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
38. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
[TBL] [Abstract][Full Text] [Related]
40. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
